Research programme: Huntington's disease RNAi therapies - Armata Pharmaceuticals
Alternative Names: AAV-siRNA; AAV1.shHD2.1; shHD2.1; short hairpin RNAs for Huntington's diseaseLatest Information Update: 01 Apr 2022
At a glance
- Originator Sirna Therapeutics; Targeted Genetics
- Developer AmpliPhi Biosciences Corporation; University of Iowa
- Class RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Huntington's disease
Most Recent Events
- 09 May 2019 C3J Therapeutics has merged with AmpliPhi Biosciences Corporation to form Armata Pharmaceuticals
- 04 Nov 2017 No recent reports of development identified for preclinical development in Huntington's-disease in USA (Parenteral, Injection)
- 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis